SCHEMBL3131303

SCHEMBL3131303

COc1cc(NC(=S)NC(=O)C=Cc2ccco2)ccc1-c1cc2ccccc2oc1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.58
ALDH1A1 P00352 8/20 0.58
POLB P06746 7/20 0.58
KDM4E B2RXH2 7/20 0.58
LMNA P02545 6/20 0.58
RAB9A P51151 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
USP2 O75604 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
KMT2A Q03164 14/20 0.57
MEN1 O00255 12/20 0.57
HPGD P15428 5/20 0.57
HTT P42858 2/20 0.57
RECQL P46063 2/20 0.57
ALOX12 P18054 1/20 0.57
BLM P54132 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
THRB P10828 1/20 0.53
EIF4H Q15056 1/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3131280 1.00 MAPT (0.58) MAPTALDH1A1POLBKDM4ELMNA
SCHEMBL13757053 0.90 KMT2A (0.53) MAPTALDH1A1POLBKDM4ELMNA
SCHEMBL3121829 0.90 KMT2A (0.53) MAPTALDH1A1POLBKDM4ELMNA
SCHEMBL3124645 0.85 MAPT (0.57) MAPTALDH1A1POLBKDM4ELMNA
SCHEMBL3124676 0.85 MAPT (0.57) MAPTALDH1A1POLBKDM4ELMNA
SCHEMBL3123056 0.84 MAPT (0.56) MAPTALDH1A1POLBKDM4ELMNA
SCHEMBL3123041 0.84 MAPT (0.56) MAPTALDH1A1POLBKDM4ELMNA
SCHEMBL3134288 0.83 MAPT (0.52) MAPTALDH1A1KDM4ELMNARAB9A
SCHEMBL3131343 0.81 MAPT (0.53) MAPTALDH1A1POLBKDM4ELMNA
SCHEMBL3131353 0.81 MAPT (0.53) MAPTALDH1A1POLBKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1860104-A1 Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof Aptanomics (FR) 2007-11-28 EP claimed
EP-2021333-B1 ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF EOS ETHICAL ONCOLOGY SCIENCE S (IT) 2010-07-14 EP disclosed
US-20090203685-A1 ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) 2009-08-13 US disclosed
EP-2021333-A2 ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF EOS - Ethical Oncology Science S.p.A. (IT) 2009-02-11 EP disclosed
WO-2007135565-A2 ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) 2007-11-29 WO disclosed
EP-1860104-A1 Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof Aptanomics (FR) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203685-A1 ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF MKI67, CCNA1, CCNI MAPT 4821/4885ALDH1A1 376/4885POLB 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.